• 방재와보험
• /
• s.62
• /
• pp.42-45
• /
• 1994

• Proceedings of the Korean Society of Applied Pharmacology
• /
• 2005.11a
• /
• pp.10-14
• /
• 2005

• Journal of Welding and Joining
• /
• v.28 no.4
• /
• pp.5-8
• /
• 2010

• Proceedings of the Population Association of Korea Conference
• /
• 2006.12a
• /
• pp.233-243
• /
• 2006

• Journal of the Chungcheong Mathematical Society
• /
• v.5 no.1
• /
• pp.49-56
• /
• 1992

• JOURNAL OF ELECTRICAL WORLD
• /
• s.387
• /
• pp.44-50
• /
• 2009

• 지반과기술
• /
• v.4 no.3
• /
• pp.61-77
• /
• 2007

• Bulletin of the Korean Chemical Society
• /
• v.22 no.9
• /
• pp.943-944
• /
• 2001

• Proceedings of the PSK Conference
• /
• 2003.10b
• /
• pp.187.1-187.1
• /
• 2003

Type 2 diabetes is characterized by high level of blood glucose and insulin and impaired action. In recent years, the treatment of type 2 diabetes has been revolutionized with the advent of thiazolidinedione (TZD) class of molecules that ameliorate insulin resistance and thereby normalize elevated blood glucose levels. These TZDs are synthetic, high-affinity ligands of peroxisome proliferator activated receptor-gamma (PPAR${\gamma}$); a member of the nuclear receptor family that controls the expression of genes in the target tissues of insulin action. (omitted)

• 대한생식의학회:학술대회논문집
• /
• 2004.06a
• /
• pp.93-94
• /
• 2004